NCT03500679View on ClinicalTrials.gov

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

PHASE2CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

May 9, 2018

Primary Completion Date

November 5, 2018

Study Completion Date

June 11, 2019

Conditions

Healthy

Interventions

BIOLOGICAL

ExPEC4V

Participants will receive ExPEC4V vaccine as an IM injection on Days 1 and 181.

BIOLOGICAL

Placebo

Participants will receive placebo as an IM injection on Days 1 and 181.

Trial Locations (2)

37920

VGR & NOCCR - Knoxville, Knoxville

67207

Heartland Clinical Research, Wichita

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT03500679 - A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older | Biotech Hunter | Biotech Hunter